This webinar will explain the EPISEEK™ multi-cancer detection testing process and the significance of the test results. Shared (or supported) decision making is an essential part of the patient care experience. The clinician will have a better understanding of test performance and how to counsel patients with "NO CANCER SIGNAL DETECTED" and "ABNORMAL METHYLATION SIGNAL DETECTED" results.
Precision Epigenomics is an innovative molecular diagnostics company focused on earlier detection and better outcomes for cancer patients. The company is known for its knowledgeable staff, commitment to patient care, and absolute dedication to quality. For additional information regarding Precision Epigenomics and its EPISEEK™ testing, please visit the company website at https://precision-epigenomics.com/.
Speaker: Richard Bernert, MD, FCAP, COO of Precision Epigenomics
